D. E. Danilau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
D. E. Danilau has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- D.V. Litvinchuk
Белорусский государственный медицинский университет
2 shared publications - Igor A. Karpov
Belarusian State Medical University
2 shared publications D. Litvinchuk
1 shared publicationI. Karpov
1 shared publication- Olga V. Krasko
The United Institute of Informatics Problems of the National Academy of Sciences of Belarus
1 shared publication Д. Е. Данилов
Белорусский государственный медицинский университет
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by The Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health
- Vol. 1 (9) , 24-34
Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.
- 20 October 2026
- Published by The Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health
- Vol. 1 (9) , 24-34
Open AccessClinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (2)
Effect of tocilizumab on COVID-19 outcomes in hospitalized patients
- 1 January 2026
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 15 (2)
Effect of tocilizumab on COVID-19 outcomes in hospitalized patients
- Open Access
- 30 June 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 140-146
Cytolytic syndrome associated with the treatment for COVID-19
The article describes a clinical case of an increased level of hepatic transaminases during a delayed period of the treatment in a patient with coronavirus disease COVID-19 using remdesivir and a possible effect of hepatic steatosis on the severity of cytolytic syndrome associated with the course of COVID-19.
- 30 June 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 140-146
Open AccessCytolytic syndrome associated with the treatment for COVID-19
The article describes a clinical case of an increased level of hepatic transaminases during a delayed period of the treatment in a patient with coronavirus disease COVID-19 using remdesivir and a possible effect of hepatic steatosis on the severity of cytolytic syndrome associated with the course of COVID-19.
- Open Access
- 1 January 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (2) , 184-188
THE USE OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is signifcantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not signifcantly affect hematological parameters, are well tolerated, and have acceptable safety profle.
- 1 January 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (2) , 184-188
Open AccessTHE USE OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is signifcantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not signifcantly affect hematological parameters, are well tolerated, and have acceptable safety profle.